Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Advancements in Novel Nanomaterials for Cancer Therapy and Diagnosis
share announcement

Advancements in Novel Nanomaterials for Cancer Therapy and Diagnosis

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 3305

Special Issue Editors

Dr. Ponnuchamy Kumar

E-Mail Website
Guest Editor
Food Chemistry and Molecular Cancer Biology Lab, Department of Animal Health and Management, Alagappa University, Karaikudi 630003, Tamil Nadu, India
Interests: nanomaterials; molecular cancer biology; apoptosis; cell signaling; toxicogenomics
Dr. Puneet Khandelwal

E-Mail Website
Guest Editor
The Division of Cancer Imaging Research, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Interests: nanotechnology; nanomedicine; non-viral gene delivery; cancer therapy; super-resolution microscopy
Dr. Mariya Gover Antoniraj

E-Mail Website
Guest Editor
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of Negev, Beer Sheva, Israel
Interests: pharmaceutical formulation; food nanotechnology; immunotherapy

Special Issue Information

Dear Colleagues,

Nanotechnology is a relatively new field with the potential to create new technology for more accurate and efficient cancer treatment and diagnosis. Nanotechnology deals with developing nanomaterials with a high surface area-to-volume ratio and possessing unique optical, magnetic, and electrical properties. Due to these properties, nanomaterials are being thoroughly researched for their potential in cancer therapy and have caught the attention of researchers worldwide. Nanotechnology utilizes a wide array of materials ranging from biological to synthetic origins, to fabricate tiny particles, which have excellent abilities in terms of physicochemical properties and is widely being studied to illustrate their biological interactions. These nanotechnology-derived products showed promising results in treating several human ailments. However, more attention is given to treating highly complicated proliferative diseases. Multiple approaches have been studied, including size-based efficiency and surface property-mediated proficiency and so on, examined to control the progression of cancer effectively. In the concept of targeting disease, passive-to-active targeting has been researched. By the time research has been extended to not just the target tumor cells, its focus on tumor microenvironment targeting has proved to have better outcomes in reducing disease. Moreover, nanotechnology-derived immunotherapy depicts an exceptional ability in suppressing cancer development; however, there is a long way to go to attain side-effect-free effective nanotoxic materials for the treatment of diverse cancer diseases.

The goal of this Special Issue is to document developments in nanomaterials for cancer therapy and diagnosis. We welcome articles involving nanoparticles targeting cancer in all aspects and invite researchers to publish their original research or review articles with expert opinions and perspectives in the above-mentioned fields.

Dr. Ponnuchamy Kumar
Dr. Puneet Khandelwal
Dr. Mariya Gover Antoniraj 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomaterials
  • nanotechnology
  • nanoparticles
  • nanomedicine
  • surface charge
  • cancer
  • apoptosis
  • mitochondria
  • immunotherapy
  • tumor microenvironment
  • liposomes
  • lipid nanoparticles
  • polymer nanoparticles
  • cancer
  • drug delivery
  • gene delivery

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2883 KiB  
Article
Improve BBB Penetration and Cytotoxicity of Palbociclib in U87-MG Glioblastoma Cells Delivered by Dual Peptide Functionalized Nanoparticles
by Yu-Chen Lo and Wen-Jen Lin
Pharmaceutics 2023, 15(10), 2429; https://doi.org/10.3390/pharmaceutics15102429 - 06 Oct 2023
Cited by 2 | Viewed by 1223
Abstract
Palbociclib (PBC) is an FDA-approved CDK4/6 inhibitor used for breast cancer treatment. PBC has been demonstrated its ability to suppress the proliferation of glioma cells by inducing cell cycle arrest. However, the efflux transporters on the blood-brain barrier (BBB) restricts the delivery of [...] Read more.
Palbociclib (PBC) is an FDA-approved CDK4/6 inhibitor used for breast cancer treatment. PBC has been demonstrated its ability to suppress the proliferation of glioma cells by inducing cell cycle arrest. However, the efflux transporters on the blood-brain barrier (BBB) restricts the delivery of PBC to the brain. The nano-delivery strategy with BBB-penetrating and glioma-targeting abilities was designed. Poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) was functionalized with the potential peptide, T7 targeting peptide and/or R9 penetrating peptide, to prepare PBC-loaded nanoparticles (PBC@NPs). The size of PBC@NPs was in the range of 168.4 ± 4.3–185.8 ± 4.4 nm (PDI < 0.2), and the zeta potential ranged from −17.8 ± 1.4 mV to −14.3 ± 1.0 mV dependent of conjugated peptide. The transport of PBC@NPs across the bEnd.3 cell model was in the order of dual-peptide modified NPs > T7-peptide modified NPs > peptide-free NPs > free PBC, indicating facilitated delivery of PBC by NPs, particularly the T7/R9 dual-peptide modified NPs. Moreover, PBC@NPs significantly enhanced U87-MG glioma cell apoptosis by 2.3–6.5 folds relative to PBC, where the dual-peptide modified NPs was the most effective one. In conclusion, the PBC loaded dual-peptide functionalized NPs improved cellular uptake in bEnd.3 cells followed by targeting to U87-MG glioma cells, leading to effective cytotoxicity and promoting cell death. Full article
(This article belongs to the Special Issue Advancements in Novel Nanomaterials for Cancer Therapy and Diagnosis)
►▼ Show Figures

Figure 1

21 pages, 8482 KiB  
Article
Mannose-Coated Reconstituted Lipoprotein Nanoparticles for the Targeting of Tumor-Associated Macrophages: Optimization, Characterization, and In Vitro Evaluation of Effectiveness
by Akpedje S. Dossou, Morgan E. Mantsch, Ammar Kapic, William L. Burnett, Nirupama Sabnis, Jeffery L. Coffer, Rance E. Berg, Rafal Fudala and Andras G. Lacko
Pharmaceutics 2023, 15(6), 1685; https://doi.org/10.3390/pharmaceutics15061685 - 08 Jun 2023
Cited by 4 | Viewed by 1578
Abstract
Reconstituted high-density lipoprotein nanoparticles (rHDL NPs) have been utilized as delivery vehicles to a variety of targets, including cancer cells. However, the modification of rHDL NPs for the targeting of the pro-tumoral tumor-associated macrophages (TAMs) remains largely unexplored. The presence of mannose on [...] Read more.
Reconstituted high-density lipoprotein nanoparticles (rHDL NPs) have been utilized as delivery vehicles to a variety of targets, including cancer cells. However, the modification of rHDL NPs for the targeting of the pro-tumoral tumor-associated macrophages (TAMs) remains largely unexplored. The presence of mannose on nanoparticles can facilitate the targeting of TAMs which highly express the mannose receptor at their surface. Here, we optimized and characterized mannose-coated rHDL NPs loaded with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an immunomodulatory drug. Lipids, recombinant apolipoprotein A-I, DMXAA, and different amounts of DSPE-PEG-mannose (DPM) were combined to assemble rHDL-DPM-DMXAA NPs. The introduction of DPM in the nanoparticle assembly altered the particle size, zeta potential, elution pattern, and DMXAA entrapment efficiency of the rHDL NPs. Collectively, the changes in physicochemical characteristics of rHDL NPs upon the addition of the mannose moiety DPM indicated that the rHDL-DPM-DMXAA NPs were successfully assembled. The rHDL-DPM-DMXAA NPs induced an immunostimulatory phenotype in macrophages pre-exposed to cancer cell-conditioned media. Furthermore, rHDL-DPM NPs delivered their payload more readily to macrophages than cancer cells. Considering the effects of the rHDL-DPM-DMXAA NPs on macrophages, the rHDL-DPM NPs have the potential to serve as a drug delivery platform for the selective targeting of TAMs. Full article
(This article belongs to the Special Issue Advancements in Novel Nanomaterials for Cancer Therapy and Diagnosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop